Machulda, Mary M.

Abstract Disruption of the default mode network is a hallmark of Alzheimer’s disease, which has not been extensively examined in atypical phenotypes. We investigated cross-sectional and 1-year longitudinal changes in default mode network sub-systems in the visual and language variants of Alzheimer’s disease, in relation to age and tau. Sixty-one amyloid-positive Alzheimer’s disease participants diagnosed with posterior cortical atrophy (n = 33) or logopenic progressive aphasia (n = 28) underwent structural MRI, resting-state functional MRI and [18F]flortaucipir PET. One-hundred and twenty-two amyloid-negative cognitively unimpaired individuals and 60 amyloid-positive individuals diagnosed with amnestic Alzheimer’s disease were included as controls and as a comparison group, respectively, and had structural and resting-state functional MRI. Forty-one atypical Alzheimer’s disease participants, 26 amnestic Alzheimer’s disease participants and 40 cognitively unimpaired individuals had one follow-up functional MRI ∼1–2 years after the baseline scan. Default mode network connectivity was calculated using the dual regression method for posterior, ventral, anterior ventral and anterior dorsal sub-systems derived from independent component analysis. A global measure of default mode network connectivity, the network failure quotient, was also calculated. Linear mixed-effects models and voxel-based analyses were computed for each connectivity measure. Both atypical and amnestic Alzheimer’s disease participants had lower cross-sectional posterior and ventral and higher anterior dorsal connectivity and network failure quotient relative to cognitively unimpaired individuals. Age had opposite effects on connectivity in Alzheimer’s disease participants and cognitively unimpaired individuals. While connectivity declined with age in cognitively unimpaired individuals, younger Alzheimer’s disease participants had lower connectivity than the older ones, particularly in the ventral default mode network. Greater baseline tau-PET uptake was associated with lower ventral and anterior ventral default mode network connectivity in atypical Alzheimer’s disease. Connectivity in the ventral default mode network declined over time in atypical Alzheimer’s disease, particularly in older participants, with lower tau burden. Voxel-based analyses validated the findings of higher anterior dorsal default mode network connectivity, lower posterior and ventral default mode network connectivity and decline in ventral default mode network connectivity over time in atypical Alzheimer’s disease. Visuospatial symptoms were associated with default mode network connectivity disruption. In summary, default mode connectivity disruption was similar between atypical and amnestic Alzheimer’s disease variants, and discriminated Alzheimer’s disease from cognitively unimpaired individuals, with decreased posterior and increased anterior connectivity and with disruption more pronounced in younger participants. The ventral default mode network declined over time in atypical Alzheimer’s disease, suggesting a shift in default mode network connectivity likely related to tau pathology.

Abstract Background Progressive apraxia of speech (PAOS) is characterized by difficulties with motor speech programming and planning. PAOS targets gray matter (GM) and white matter (WM) microstructure that can be assessed using diffusion tensor imaging (DTI) and multishell applications, such as neurite orientation dispersion and density imaging (NODDI). In this study, we aimed to apply DTI and NODDI to add further insight into PAOS tissue microstructure. Methods Twenty‐two PAOS patients and 26 age‐ and sex‐matched controls, recruited by the Neurodegenerative Research Group (NRG) at Mayo Clinic, underwent diffusion MRI on 3T MRI. Brain maps of fractional anisotropy (FA) and mean diffusivity (MD) from DTI and intracellular volume fraction (ICVF) and isotropic volume fraction (IsoVF) from NODDI were generated. Global WM and GM, and specific WM tracts were identified using tractography and lobar GM regions. Results Global WM differences between PAOS and controls were greatest for ICVF, and global GM differences were greatest for MD and IsoVF. Abnormalities in key WM tracts involved in PAOS, including the body of the corpus callosum and frontal aslant tract, were identified with FA, MD, and ICVF, with excellent differentiation of PAOS from controls (area under the receiver operating characteristic curves >.90). MD and ICVF identified abnormalities in arcuate fasciculus, thalamic radiations, and corticostriatal tracts. Significant correlations were identified between an index of articulatory errors and DTI and NODDI metrics from the arcuate fasciculus, frontal aslant tract, and inferior longitudinal fasciculus. Conclusions DTI and NODDI represent different aspects of brain tissue microstructure, increasing the number of potential biomarkers for PAOS.

AbstractINTRODUCTIONThe implications of positive tau positron emission tomography (T) with negative beta amyloid positron emission tomography (A) are not well understood. We investigated cognitive performance in participants who were T+ but A‐.METHODSWe evaluated 98 participants from the Mayo Clinic who were T+ and A‐. Participants were matched 2:1 to A‐ and T‐ cognitively unimpaired (CU) controls. Cognitive test scores were compared between different groups.RESULTSThe A‐T+ group demonstrated lower performance than the A‐T‐ group on the Mini‐Mental Status Exam (MMSE) (p < 0.001), Wechsler Memory Scale‐Revised Logical Memory I (p < 0.001) and Logical Memory II (p < 0.001), Auditory Verbal Learning Test (AVLT) delayed recall (p = 0.004), category fluency (animals p = 0.005; vegetables p = 0.021), Trail Making Test A and B (p < 0.001), and others. There were no significant differences in demographic features or apolipoprotein E (APOE) e4 genotype between CU A‐T+ and CI A‐T+.DISCUSSIONA‐T+ participants show an association with lower cognitive performance.

AbstractBackgroundThe mapping between risk factors and biomarkers with cognitive performance and decline in the older adults is complex and varies significantly across different age and sex groups. Our goals were to (i) develop a machine learning (ML) model to predict baseline cognition and cognitive decline over a 5‐year follow‐up using only baseline assessments, and (ii) identify important modifiable and non‐modifiable predictors of cognitive decline across different age strata.MethodWe utilized longitudinal data from 2219 participants (mean age (SD): 70 (12) years, 49% male) from Mayo Clinic Study of Aging who had 43 features belonging to cardiovascular health, plasma, MRI (diffusion and structural), and lifestyle measures. Cognition was measured using a global cognition z‐score. We built ML models to predict baseline cognition and rate of cognitive decline over 5‐years (linear regression slopes over all individual followup measurements for each participant) using baseline assessments as inputs. We then built a model for each category separately and as a pooled model with all measures included, incorporating education and sex as demographic features in all models (Fig. 1). We applied a multi‐layer stack ensemble ML technique that utilized repeated k‐fold bagging to maximize accuracy. Importance of the top predictors were assessed in three age strata (55‐65 years (31%), 65‐80 years (46%), 80‐95 years (23%)).ResultThe pooled model explained the largest variance for prediction of baseline cognition and cognitive decline (Fig. 2). In individuals ≤80 years, lower NfL was most predictive of higher baseline cognition. A combination of imaging and plasma features predicted the 5‐year cognitive decline. Additionally, in individuals ≤65 years, diabetes and hypertension were important predictors of faster cognitive decline and in those >80, lower BMI and midlife physical/cognitive activity was an important predictor of faster cognitive decline (Fig. 3).ConclusionThe plasma model was best for baseline cognition prediction and imaging model was best for cognitive decline prediction. There was significant heterogeneity in important features across the age strata. In individuals >65 years, plasma GFAP was the most important predictor of cognitive decline. Our model allowed identification of key risk factors that predicted cognitive decline.

AbstractBackgroundThe implications of a positive tau (T) Positron Emission Tomography (PET) with a negative beta amyloid (A) PET are not well understood. We investigated cognitive performance in participants who were positive on tau PET but negative on beta amyloid PET.MethodWe evaluated 98 participants from the Mayo Clinic Study of Aging (MCSA) and the Mayo Clinic Alzheimer’s Disease Research Center (ADRC) who were positive for Flortaucipir (FTP) and negative for PiB PET. Participants were classified as A‐ and T+ based on Standardized Uptake Value Ratios (SUVr) of FTP and PiB PET scans, and were matched 2:1 to amyloid negative and tau negative cognitively unimpaired controls from the MCSA. Cognitive test scores were compared between the combined ADRC/MCSA group and MCSA only group. We also examined clinical diagnoses in our cohort. The most common were Alzheimer’s Disease, mild cognitive impairment (MCI), Dementia with Lewy Bodies (DLB) and Frontotemporal dementia (FTD) amongst others.ResultThere were no significant differences in demographic features or PiB SUVr between groups. There were significant differences in APOE genotype between groups. In the combined ADRC/MCSA group, 25% of A‐T‐ and 13% of A‐T+ were APOE e4 carriers (p = 0.016), and in the MCSA only group, 27% of A‐T‐and 10% of A‐T+ were APOE e4 carriers (p = 0.010). In the combined ADRC/MCSA group, the A‐T+ group demonstrated lower performance than the A‐T‐ group on the Mini Mental Status Exam (MMSE) (p<0.001), Wechsler Memory Scale‐Revised Logical Memory I (p<0.001) and Logical Memory II (p<0.001), Auditory verbal Learning Test Delayed Recall (AVLT) (p = 0.004), Category fluency animals (p = 0.005), Category fluency vegetables (p = 0.021), Trailmaking test A (p<0.001), Trail making test B (p<0.001), Wechsler Adult Intelligence Scale‐IV (WAIS‐IV) (p = 0.002), and Unified Parkinson’s Disease Rating Scale part III (UPDRS III) (p = 0.003). In the MCSA only group, the A‐T+ group had lower scores on Logical Memory II (p = 0.022), AVLT delated recall (p = 0.04), and WAIS‐R block design (p = 0.035) compared to the A‐T‐group.ConclusionPositive tau PET in the absence of beta‐amyloid positivity is associated with lower cognitive performance.

AbstractBackgroundEasily accessible and self‐administered cognitive assessments that can aide early identification of individuals at risk for Alzheimer’s disease (AD) dementia are critical for timely intervention. Mayo Test Drive (MTD) is a remote, self‐administered, multi‐device compatible, web‐based cognitive assessment (Stricker et al., 2022). We investigated continuous associations between MTD and amyloid and tau PET biomarkers and compared the strength of association to PET biomarkers and in‐person cognitive measures.Method556 adults from the Mayo Clinic Study of Aging participated (mean age = 70.6; mean education = 16.0 years; 50.7% female; 97.5% white). Participants were predominantly cognitively unimpaired (95.3%; 4.7% had a consensus diagnosis of mild cognitive impairment). Participants completed (1) brain amyloid and tau PET scans, (2) in‐person neuropsychological assessment including Mayo Preclinical Alzheimer’s disease Cognitive Composite (Mayo‐PACC) and Global‐z, and (3) remote MTD comprised of the Stricker Learning Span (SLS) and the Symbols test, which are combined into an MTD composite. Multiple regressions adjusted for age, sex, and education queried associations between imaging biomarkers [amyloid meta‐region of interest (ROI), tau meta‐ROI, and tau entorhinal cortex (EC)‐ROI)] and composite and subtest scores from remote and in‐person measures. Davidson‐Mackinnon J‐test compared R‐squared values of models with remote versus in‐person composites.ResultLower performances on MTD composite and Mayo‐PACC were associated with higher amyloid meta‐ROI (p’s<.05; Table 1). MTD composite was also negatively associated with tau meta‐ROI and EC‐ROI (p’s<.05). For memory measures, SLS sum of trials was negatively associated with tau meta‐ROI (p = .01) and EC‐ROI (p<.001) with no associations between AVLT sum of trials and PET (p’s≥.06; Table 2). Among processing speed/executive function measures, worse Trails B performance was associated with higher amyloid meta‐ROI (p<.001). Symbols and Digit Symbol Coding were not associated with PET (p’s≥.29). A multivariable model with MTD explained significantly less variance (p = .04) for amyloid meta‐ROI (adjusted R‐squared = 0.165) than a multivariable model with Mayo‐PACC (adjusted R‐squared = 0.176); remote and in‐person composite measures were comparable for other associations (p’s>.05).ConclusionMTD is associated with continuous measures of amyloid and tau PET biomarkers of AD, demonstrating criterion validity for MTD. Several associations were comparable to relationships between gold‐standard in‐person neuropsychological tests and imaging biomarkers.

AbstractBackgroundBrief self‐administered cognitive assessments deployed remotely and combined with plasma biomarkers of Alzheimer’s disease (AD) are well suited to assess clinical symptoms and underlying biology in large‐scale decentralized studies. We investigated whether associations of self‐administered cognitive measures and plasma biomarkers were comparable to associations of in‐person cognitive measures and plasma biomarkers.MethodParticipants included 327 adults from the Mayo Clinic Study of Aging (mean age = 70.8; 48% female; mean education = 16.0 years; 96.9% white). Most (94.5%) were cognitively unimpaired; 5.5% had consensus diagnosis of mild cognitive impairment. Participants completed Mayo Test Drive (MTD; Stricker et al., 2022), a remote, self‐administered, multi‐device compatible web‐based cognitive assessment comprised of the Stricker Learning Span (SLS) and Symbols test that are combined into a MTD composite. Participants also completed in‐person neuropsychological assessment (global‐z; Mayo Preclinical Alzheimer’s disease Cognitive Composite [Mayo‐PACC]) and fasting venipuncture. Plasma was assayed via HD‐X simoa platform for amyloid‐beta (Aβ)‐42 and Aβ‐40 to create an Aβ42/40 ratio, glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) using the N4PE Quanterix kit as well as phosphorylated‐tau protein 181 (p‐tau181). P‐tau181, GFAP, and NfL were log10‐transformed. Multiple regression analyses adjusting for age, sex, and education examined associations between plasma biomarkers and composite and subtest scores from remote and in‐person measures. Davidson‐Mackinnon J‐test compared R‐squared values of models with remote versus in‐person composites.ResultLower performances on MTD, global‐z, and Mayo‐PACC (Table 1) were associated with higher GFAP (p’s≤.02), NfL (p’s≤.003), and p‐tau181 (p’s = .04). For memory, worse SLS and AVLT sum of trials were associated with higher GFAP (p’s≤.01) and NfL (p’s≤.03). For processing speed/executive function, worse Symbols and Trails B were associated with higher p‐tau181 (p’s≤.02). Worse Trails B and Digit Symbol Coding were associated with higher NfL (p’s≤.02), and worse Digit Symbol Coding was associated with lower Aβ42/40 (p = 0.03; Table 2). A multivariable model with MTD explained significantly more variance (p = .04) for NfL (adjusted R‐squared = 0.461) than a multivariable model with Mayo‐PACC (adjusted R‐squared = 0.447); remote and in‐person composite measures were comparable for other associations (p’s>.05).ConclusionRemote and in‐person composite measures showed comparable associations with AD‐related plasma biomarkers, supporting MTD’s criterion validity.

AbstractBackgroundThe language and visual variants are two common clinical phenotypes of atypical Alzheimer’s disease (AD). There are reports of overlap between these clinical phenotypes, however, the extent and frequency of overlap, and its neuroanatomical underpinnings remain unclear.MethodEighty‐two patients with biomarker‐confirmed AD who presented with either predominant language (n = 34) or visuospatial/perceptual (n = 48) deficits were recruited by the Neurodegenerative Research Group and underwent neurological and neuropsychological testing, MRI and [18F]flortaucipir‐PET. The clinical examination included testing for simultanagnosia, Gerstmann’s syndrome, ideomotor apraxia, visuospatial‐visuoperceptual function, confrontational naming, sentence repetition and letter and animal fluency. Cut‐points for abnormality were defined for each test and used to classify the following groups: language‐pure (no visual‐function deficit), language‐plus (impaired on one visual‐function), language‐mixed (impaired on two visual‐functions), visual‐pure (no language‐function deficit), visual‐plus (impaired on one language‐function) and visual‐mixed (impaired on two language‐functions). Patterns of relative volume loss and flortaucipir uptake were assessed using SPM12.ResultOf the 82 patients, 11 (13%) were language‐pure, 16 (20%) language‐plus, 7 (8%) language‐mixed, 10 (12%) visual‐pure, 17 (21%) visual‐plus and 21 (26%) visual‐mixed, with no difference in disease duration across groups. Visual deficits in the language‐plus group consisted of mild simultanagnosia in 29%, Gerstmann’s syndrome in 24%, and mild visuospatial deficits. In the language‐mixed group 86% had simultanagnosia and 43% had Gerstmann’s syndrome, with visuospatial‐visuoperceptual deficits comparable to the visual‐pure group. Language deficits in the visual‐plus group consisted of mild anomia and reduced letter and animal fluency. The visual‐mixed group reported naming and repetition deficits, and reduced fluency, comparable to the language‐predominant groups. All three language groups showed left temporal volume loss and flortaucipir uptake, with greater involvement of the parieto‐occipital and frontal lobes in language‐plus and language‐mixed groups. All three visual groups showed occipital volume loss and flortaucipir uptake, with greater involvement of the parieto‐temporal and frontal lobes in visual‐plus and visual‐mixed groups.ConclusionOnly 25% of our cohort showed a pure language or visual presentation, highlighting the high frequency of syndromic overlap in atypical AD and the diagnostic challenge of categorical phenotyping. Syndromic overlap was associated with neuroanatomical overlap and more widespread patterns of atrophy and tau deposition.

AbstractBackgroundPosterior cortical atrophy (PCA) and dementia with Lewy bodies (DLB) show overlapping patterns of hypometabolism affecting posterior regions of the brain. Both syndromes show disruptions in functional connectivity, but it is unknown how patterns of disruption within and between networks compare between PCA and DLB.MethodThirty amyloid‐positive PCA, 27 amyloid‐positive DLB (DLB+), 24 amyloid‐negative DLB (DLB‐) patients and 30 cognitively normal amyloid‐negative (CN) individuals were recruited at Mayo Clinic, Rochester, MN, and underwent structural and resting state functional MRI. Spatially preprocessed data was analyzed using the CONN functional connectivity toolbox to explore nine networks: visual, sensorimotor, dorsal‐attention, cerebellar, frontoparietal, memory, language, salience, and default mode networks (DMN). Multivariate linear regression models corrected for multiple comparisons and adjusted for age and sex were fit to analyze within‐network connectivity (Fisher’s R‐to‐Z transformations). Between‐network connectivity was assessed with group level difference maps (two‐sample t‐test) corrected for false discovery rate at p<0.05.ResultMultivariate linear regression models showed reduced within‐network connectivity across all DMN components, sensorimotor, and dorsal‐attention networks, with trends for the visual network in PCA compared to CN. Both DLB‐ and DLB+ showed reduced within‐network connectivity for the cerebellar network, with DLB+ showing reduced connectivity in the posterior‐DMN, memory, and salience networks compared to CN. DLB‐ showed increased connectivity in dorsal‐attention and DMN, while DLB+ showing reduced connectivity in the memory network compared to PCA. Between‐network analysis showed an increase in cerebellar‐to‐sensorimotor connectivity in all three groups, with increase in cerebellar‐to‐dorsal‐attention connectivity in DLB‐ and PCA compared to CN. DLB‐ showed a decrease in posterior‐DMN‐to‐sensorimotor connectivity, while PCA showed reduced connectivity between all DMN components and dorsal‐attention‐to‐sensorimotor connectivity compared to CN. There was an increase in connectivity between all DMN components and a reduction in dorsal‐DMN‐to‐sensorimotor connectivity in both DLB‐ and DLB+ compared to PCA.ConclusionPCA was associated with connectivity disruptions across all DMN components, sensorimotor, dorsal‐attention and visual networks, while both DLB groups showed disruptions in cerebellar networks, with DLB+ showing further disruptions in posterior‐DMN, memory and salience networks. These findings suggest that both PCA and DLB have unique brain network disruptions, with amyloid status influencing connectivity in DLB.

AbstractBackgroundSmall vessel disease (SVD) is a common vascular contributor to cognitive impairment and dementia. In this work, we evaluated and compared non‐imaging measures that can predict variability in SVD related white matter (WM) damage in a population‐based sample.MethodWe identified 752 participants in the population‐based sample of Mayo Clinic Study of Aging (≥50 years of age), who had at least 2 diffusion tensor imaging (DTI) scans and white matter hyperintensity (WMH) assessments along with baseline demographics, systemic vascular health, lifestyle, motor impairment, behavioral symptoms, and plasma markers (Summarized in Figure 1). We computed the WM markers of SVD: fractional anisotropy of genu of the corpus callosum (Genu‐FA) representative of early WM changes, WMH representative of late WM changes, and Vascular WM score (combination of Genu‐FA and WMH). Using all available data, we fit linear mixed effect models and evaluated predictors of WM markers by considering each category of features independently (with demographics) as well as by combining all categories of featuresResultPlasma, gait, systemic vascular, and life‐style measures were significant predictors of all three WM markers of SVD (Figure 2). The predictors of early and late WM slightly differed such that there were no additional significant contributions from behavioral and plasma measures to Genu‐FA. In the final composite models shown in Table 1, higher gait speed, lower number of cardiovascular and metabolic conditions (CMC) and lower Unified Parkinson’s disease rating scale scores were associated with better Genu‐FA whereas higher CMC, Beck Anxiety Inventory scores (BAI), and glial acidic protein (GFAP) levels were associated with higher burden of WMH.ConclusionOur observations evaluated the non‐imaging markers of greater WM damage that are relevant to vascular contributions to cognitive impairment to dementia (VCID). We found that in addition to higher vascular risk, worse plasma GFAP, gait measures, and BAI scores were predictors of greater WM damage. Some non‐imaging markers were more associated with early WM changes and others with late WM changes.